<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940711-2-00102</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>National Institutes of Health</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Government-Owned Inventions; Availability for Licensing </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  National Institutes of Health.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ACTION> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to Steven M. Ferguson, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, suite 325, Rockville, Maryland 20852&hyph;3804 (telephone 301/496&hyph;7735 ext. 266; fax 301/402&hyph;0220). A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Issued patents may be obtained from the Commissioner of Patents, U.S. Patent and Trademark Office, Washington, DC 20231.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Anti-Retroviral Compounds  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Tam, S., Weigle, M., Broder, S., Mitsuya, H. (NCI)  <!-- PJG 0012 frnewline --> Serial No. 07/064,631  <!-- PJG 0012 frnewline --> Patent Reissued 14 Apr 92  <!-- PJG 0012 frnewline --> U.S. Patent No. Re 33,887  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Dimeric dideoxynucleosides formed from two different 2 <!-- PJG 0020 minuteslatlong --> &rsquo;,3 <!-- PJG 0020 minuteslatlong --> &rsquo;- dideoxynucleosides joined by a linking group are useful for treatment of HIV-infection and other retroviral infections. The linked dideoxynucleosides specifically inhibit HIV replication in vitro with less toxicity in human cells. Methods for the synthesis of these compounds are provided.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Method of Inhibiting Viral Replication Using IL&hyph;10  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Yarchoan, R., Saville, W., Tosato, G., Taga, K. (NCI) <!-- PJG 0012 frnewline --> Filed 24 May 93 <!-- PJG 0012 frnewline --> Serial No. 08/066,785  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> The use of recombinant human interleukin 10 (rhIL&hyph;10) has been discovered to be a new potential means of treating HIV infection. In vitro studies with rhIL&hyph;10 have shown it to be an inhibitor of HIV infection in human monocytes and macrophages as well as having activity against HIV in certain T-cell and monocyte cell lines. This activity against HIV occurs both at the time of infection and when added to previously infected cell cultures.  <!-- PJG 0012 frnewline --> These effects occur at IL&hyph;10 concentrations that are lower than those which inhibit other immune functions. In addition, the use of IL&hyph;10 to interfere with HIV replication is expected to result in the amelioration of Kaposi's sarcoma.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Novel Nonpeptidic Retroviral Protease Inhibitors  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Randad, R., Pan, W., Burt, S., Erickson, J. (NCI)  <!-- PJG 0012 frnewline --> Filed 8 Aug 93  <!-- PJG 0012 frnewline --> Serial No. 08/106,686  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Novel nonpeptidic compounds designed to be inhibitors of the HIV protease enzyme have been discovered. These compounds thus have potential as possible pharmaceutical compositions for the inhibition HIV replication and the treatment of AIDS. Based upon SS isomers of substituted dibenzyl-5-hydroxyl-2-primidones, these compounds are expected to not have the problems associated with current peptide-based protease inhibitors such as poor oral absorption, poor stability, and rapid metabolism and elimination.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Use of Peptomers Derived From HIV&hyph;1 and HIV&hyph;2 as Vaccine Candidates  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Robey, F., Harris-Kelson, T., Robert-Guroff, M. (NIDR)  <!-- PJG 0012 frnewline --> Filed 19 Jan 94  <!-- PJG 0012 frnewline --> Serial No. 08/184,330  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Novel conformationally constrained peptide polymer HIV vaccine candidates have been uncovered that generate a strong humoral immune response not seen against monomeric peptides. Termed ``peptomers'', these candidates are composed of specifically cross-linked synthetic peptide sequences from the highly conserved CD4 binding domains of the gp120 regions of HIV&hyph;1  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> and <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  HIV&hyph;2. Although peptides from these regions of gp120 do not possess any conformation in solution, the polymerized forms were found to have conformations that resemble the theoretical conformations that might be found in these regions of the native gp120 from HIV&hyph;1 and HIV&hyph;2. Certain peptomers from HIV&hyph;1 and HIV&hyph;2 bind CD4, the cell receptor for HIV&hyph;1 and HIV&hyph;2, and induce antibody responses in rabbits and rhesus monkeys that block in vitro HIV&hyph;1 infection.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: June 25, 1994.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ADDRESS> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 -->  Barbara M. McGarey,  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 -->  Deputy Director,  <!-- PJG 0012 frnewline --> Office of Technology Transfer.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;16696 Filed 7&hyph;8&hyph;94; 8:45 am]  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4140&hyph;01&hyph;P <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            